FDA’s Decision Boosts Fulcrum Therapeutics; Macy’s Beats Q2 Estimates
- August 22nd, 2023
- 357 views
Shares of Fulcrum Therapeutics, Inc. (Nasdaq: FULC) surged over 30% in pre-market trading following the announcement that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for FTX-6058, a potential treatment for sickle-cell disease (SCD).
$FULC was trading at $5.81 in pre-market, reflecting a gain of $1.89 (+48.21%).
Shifting focus, Macy’s, Inc. (NYSE: M) reported second quarter 2023 earnings at $0.26 per share, surpassing the consensus EPS estimate of $0.13. The company's quarterly sales amounted to $5.28 billion, slightly exceeding analysts' projected revenue of $5.09 billion.
In pre-market, $M was trading at $14.43, down $0.30 (-2.04%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025
Member Login